Build Your Comparison

Side-by-side financial analysis
TIL logo
TIL
CRIS logo
CRIS
JPM logo
JPM
Try popular comparisons:

Stock Comparison

TIL vs CRIS vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TIL
Instil Bio, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$54M
5Y Perf.-98.4%
CRIS
Curis, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$82M
5Y Perf.-99.8%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+110.7%

TIL vs CRIS vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TIL logoTIL
CRIS logoCRIS
JPM logoJPM
IndustryBiotechnologyBiotechnologyBanks - Diversified
Market Cap$54M$82M$896.00B
Revenue (TTM)$0.00$7M$280.33B
Net Income (TTM)$-47M$-21M$57.05B
Gross Margin99.4%60.0%
Operating Margin-485.1%25.9%
Forward P/E14.4x
Total Debt$85M$2M$942.38B
Cash & Equiv.$7M$5M$343.34B

TIL vs CRIS vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TIL
CRIS
JPM
StockMar 21Jun 26Return
Instil Bio, Inc. (TIL)1001.6-98.4%
Curis, Inc. (CRIS)1000.2-99.8%
JPMorgan Chase & Co. (JPM)100210.7+110.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: TIL vs CRIS vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JPM leads in 5 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Instil Bio, Inc. is the stronger pick specifically for growth and revenue expansion. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
TIL
Instil Bio, Inc.
The Defensive Pick

TIL is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.55, Low D/E 74.8%, current ratio 39.53x
  • 37.2% revenue growth vs CRIS's -13.4%
Best for: sleep-well-at-night
CRIS
Curis, Inc.
The Secondary Option

CRIS plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 15 yrs, beta 0.94, yield 1.9%
  • Rev growth 3.3%, EPS growth 1.5%
  • 465.8% 10Y total return vs TIL's -98.5%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthTIL logoTIL37.2% revenue growth vs CRIS's -13.4%
Quality / MarginsJPM logoJPM20.4% margin vs CRIS's -299.7%
Stability / SafetyJPM logoJPMBeta 0.94 vs CRIS's 1.93
DividendsJPM logoJPM1.9% yield; 15-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)JPM logoJPM+21.8% vs CRIS's -84.8%
Efficiency (ROA)JPM logoJPM1.3% ROA vs CRIS's -79.5%

TIL vs CRIS vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TILInstil Bio, Inc.

Segment breakdown not available.

CRISCuris, Inc.
FY 2025
Reportable Segment
100.0%$9M
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

TIL vs CRIS vs JPM — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGCRIS

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 3 of 5 comparable metrics.

JPM and TIL operate at a comparable scale, with $280.3B and $0 in trailing revenue. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to CRIS's -3.0%.

MetricTIL logoTILInstil Bio, Inc.CRIS logoCRISCuris, Inc.JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$0$7M$280.3B
EBITDAEarnings before interest/tax-$54M-$34M$81.4B
Net IncomeAfter-tax profit-$47M-$21M$57.0B
Free Cash FlowCash after capex-$34M-$29M$100.9B
Gross MarginGross profit ÷ Revenue+99.4%+60.0%
Operating MarginEBIT ÷ Revenue-4.9%+25.9%
Net MarginNet income ÷ Revenue-3.0%+20.4%
FCF MarginFCF ÷ Revenue-4.1%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year-100.0%
EPS Growth (YoY)Latest quarter vs prior year+85.6%0.0%+16.0%
JPM leads this category, winning 3 of 5 comparable metrics.

Valuation Metrics

TIL leads this category, winning 2 of 3 comparable metrics.
MetricTIL logoTILInstil Bio, Inc.CRIS logoCRISCuris, Inc.JPM logoJPMJPMorgan Chase & …
Market CapShares × price$54M$82M$896.0B
Enterprise ValueMkt cap + debt − cash$132M$78M$1.50T
Trailing P/EPrice ÷ TTM EPS-0.74x-0.73x16.00x
Forward P/EPrice ÷ next-FY EPS est.14.40x
PEG RatioP/E ÷ EPS growth rate0.90x
EV / EBITDAEnterprise value multiple18.36x
Price / SalesMarket cap ÷ Revenue8.63x3.20x
Price / BookPrice ÷ Book value/share0.46x10.15x2.47x
Price / FCFMarket cap ÷ FCF8.88x
TIL leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

JPM leads this category, winning 6 of 9 comparable metrics.

JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-139 for CRIS. CRIS carries lower financial leverage with a 0.30x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), JPM scores 5/9 vs TIL's 2/9, reflecting solid financial health.

MetricTIL logoTILInstil Bio, Inc.CRIS logoCRISCuris, Inc.JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-39.8%-138.8%+15.9%
ROA (TTM)Return on assets-22.4%-79.5%+1.3%
ROICReturn on invested capital-18.0%+4.5%
ROCEReturn on capital employed-23.3%-2.3%+8.9%
Piotroski ScoreFundamental quality 0–9235
Debt / EquityFinancial leverage0.75x0.30x2.60x
Net DebtTotal debt minus cash$79M-$3M$599.0B
Cash & Equiv.Liquid assets$7M$5M$343.3B
Total DebtShort + long-term debt$85M$2M$942.4B
Interest CoverageEBIT ÷ Interest expense-8.24x-2.47x0.74x
JPM leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $26 for CRIS. Over the past 12 months, JPM leads with a +21.8% total return vs CRIS's -84.8%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs CRIS's -70.5% — a key indicator of consistent wealth creation.

MetricTIL logoTILInstil Bio, Inc.CRIS logoCRISCuris, Inc.JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-29.7%-57.0%-0.5%
1-Year ReturnPast 12 months-78.9%-84.8%+21.8%
3-Year ReturnCumulative with dividends-29.8%-97.4%+138.2%
5-Year ReturnCumulative with dividends-97.6%-99.7%+118.2%
10-Year ReturnCumulative with dividends-98.5%-99.7%+465.8%
CAGR (3Y)Annualised 3-year return-11.1%-70.5%+33.6%
JPM leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

JPM leads this category, winning 2 of 2 comparable metrics.

JPM is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than CRIS's 1.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs CRIS's 14.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTIL logoTILInstil Bio, Inc.CRIS logoCRISCuris, Inc.JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5001.55x1.93x0.94x
52-Week HighHighest price in past year$38.50$2.94$337.25
52-Week LowLowest price in past year$5.67$0.41$262.71
% of 52W HighCurrent price vs 52-week peak+20.6%+14.3%+95.1%
RSI (14)Momentum oscillator 0–10040.932.359.1
Avg Volume (50D)Average daily shares traded26K432K7.0M
JPM leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: CRIS as "Buy", JPM as "Buy". JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.

MetricTIL logoTILInstil Bio, Inc.CRIS logoCRISCuris, Inc.JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$339.75
# AnalystsCovering analysts1861
Dividend YieldAnnual dividend ÷ price+1.9%
Dividend StreakConsecutive years of raises15
Dividend / ShareAnnual DPS$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+3.9%
Insufficient data to determine a leader in this category.
Key Takeaway

JPM leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TIL leads in 1 (Valuation Metrics).

Best OverallJPMorgan Chase & Co. (JPM)Leads 4 of 6 categories
Loading custom metrics...

TIL vs CRIS vs JPM: Key Questions Answered

8 questions · data-driven answers · updated daily

01

Is TIL or CRIS or JPM a better buy right now?

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus -13. 4% for Curis, Inc. (CRIS). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Curis, Inc. (CRIS) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — TIL or CRIS or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -99. 7% for Curis, Inc. (CRIS). Over 10 years, the gap is even starker: JPM returned +465. 8% versus CRIS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — TIL or CRIS or JPM?

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Curis, Inc. 's 1. 93β — meaning CRIS is approximately 105% more volatile than JPM relative to the S&P 500. On balance sheet safety, Curis, Inc. (CRIS) carries a lower debt/equity ratio of 30% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

04

Which is growing faster — TIL or CRIS or JPM?

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 3. 3% versus -13. 4% for Curis, Inc. (CRIS). On earnings-per-share growth, the picture is similar: Curis, Inc. grew EPS 91. 6% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — TIL or CRIS or JPM?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -80. 3% for Curis, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -348. 4% for CRIS. At the gross margin level — before operating expenses — CRIS leads at 99. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — TIL or CRIS or JPM?

In this comparison, JPM (1.

9% yield) pays a dividend. TIL, CRIS do not pay a meaningful dividend and should not be held primarily for income.

07

Is TIL or CRIS or JPM better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Curis, Inc. (CRIS) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, CRIS: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between TIL and CRIS and JPM?

These companies operate in different sectors (TIL (Healthcare) and CRIS (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TIL is a small-cap quality compounder stock; CRIS is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while TIL, CRIS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.